Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

They include MET-233i, an injectable amylin analog that is Metsera’s answer to the sector’s search for a once-monthly dosing ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

MET-233i and Metsera’s other next-generation NuSH analog peptides are also engineered with Metsera’s HALO™ lipidation platform. Oral GLP-1 RA peptide program clinical trial initiated Metsera has ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

GLP-1 medications like Ozempic and Wegovy are sprinting their way into the fitness community, changing how athletes approach training, nutrition, and performance. Here’s what’s really going ...

That’s why Amazon shoppers are turning to this affordable GLP-1 supplement that helps curb cravings. This GLP-1 Supplement on Amazon is highly effective in assisting with the natural production ...

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported ...

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...